Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

Immunity

Volumn 43, Issue 3, 2015, Pages 579-590

  Joshi, Nikhil S ^a   Akama Garren, Elliot H ^a   Lu, Yisi ^a   Lee, Da Yae ^a   Chang, Gregory P ^a   Li, Amy ^a   DuPage, Michel ^a   Tammela, Tuomas ^a   Kerper, Natanya R ^a   Farago, Anna F ^a   Robbins, Rebecca ^a   Crowley, Denise M ^a   Bronson, Roderick T ^b   Jacks, Tyler ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; PHOTOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL SYNAPSE; IMMUNOPHENOTYPING; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS MACROPHAGE; LYMPHADENOPATHY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLENOMEGALY; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED TERTIARY LYMPHOID STRUCTURE; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; NEOPLASM; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOHISTOCHEMISTRY; LUMINESCENT PROTEINS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 84941628879     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2015.08.006     Document Type: Article

References (50)

1. Aleksic M., Liddy N., Molloy P.E., Pumphrey N., Vuidepot A., Chang K.M., Jakobsen B.K. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 2012, 42:3174-3179.
2. Antonioli L., Pacher P., Vizi E.S., Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 2013, 19:355-367.
3. Beyersdorf N., Ding X., Tietze J.K., Hanke T. Characterization of mouse CD4 T cell subsets defined by expression of KLRG1. Eur. J. Immunol. 2007, 37:3445-3454.
4. Billadeau D.D., Nolz J.C., Gomez T.S. Regulation of T-cell activation by the cytoskeleton. Nat. Rev. Immunol. 2007, 7:131-143.
5. Boissonnas A., Scholer-Dahirel A., Simon-Blancal V., Pace L., Valet F., Kissenpfennig A., Sparwasser T., Malissen B., Fetler L., Amigorena S. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010, 32:266-278.
6. Bos P.D., Plitas G., Rudra D., Lee S.Y., Rudensky A.Y. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J. Exp. Med. 2013, 210:2435-2466.
7. Campbell D.J., Koch M.A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. 2011, 11:119-130.
8. Cheng G., Yuan X., Tsai M.S., Podack E.R., Yu A., Malek T.R. IL-2 receptor signaling is essential for the development of Klrg1+ terminally differentiated T regulatory cells. J. Immunol. 2012, 189:1780-1791.
9. Chung K., Wallace J., Kim S.Y., Kalyanasundaram S., Andalman A.S., Davidson T.J., Mirzabekov J.J., Zalocusky K.A., Mattis J., Denisin A.K., et al. Structural and molecular interrogation of intact biological systems. Nature 2013, 497:332-337.
10. de Chaisemartin L., Goc J., Damotte D., Validire P., Magdeleinat P., Alifano M., Cremer I., Fridman W.H., Sautès-Fridman C., Dieu-Nosjean M.C. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011, 71:6391-6399.
11. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26:4410-4417.
12. DuPage M., Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 2013, 25:192-199.
13. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., Crowley D., Chen J., Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
14. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
15. Feuerer M., Hill J.A., Kretschmer K., von Boehmer H., Mathis D., Benoist C. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc. Natl. Acad. Sci. USA 2010, 107:5919-5924.
16. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358:2704-2715.
17. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
18. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., Biota C., Doffin A.C., Durand I., Olive D., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69:2000-2009.
19. Goc J., Fridman W.H., Sautès-Fridman C., Dieu-Nosjean M.C. Characteristics of tertiary lymphoid structures in primary cancers. OncoImmunology 2013, 2:e26836.
20. Hayes S.A., Hudson A.L., Clarke S.J., Molloy M.P., Howell V.M. From mice to men: GEMMs as trial patients for new NSCLC therapies. Semin. Cell Dev. Biol. 2014, 27:118-127.
21. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
22. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
23. Josefowicz S.Z., Lu L.F., Rudensky A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 2012, 30:531-564.
24. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., Gapin L., Kaech S.M. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
25. Kaech S.M., Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat. Immunol. 2001, 2:415-422.
26. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
27. Kwon M.C., Berns A. Mouse models for lung cancer. Mol. Oncol. 2013, 7:165-177.
28. Lin W., Truong N., Grossman W.J., Haribhai D., Williams C.B., Wang J., Martín M.G., Chatila T.A. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J. Allergy Clin. Immunol. 2005, 116:1106-1115.
29. Madisen L., Zwingman T.A., Sunkin S.M., Oh S.W., Zariwala H.A., Gu H., Ng L.L., Palmiter R.D., Hawrylycz M.J., Jones A.R., et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 2010, 13:133-140.
30. Marabelle A., Kohrt H., Sagiv-Barfi I., Ajami B., Axtell R.C., Zhou G., Rajapaksa R., Green M.R., Torchia J., Brody J., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 2013, 123:2447-2463.
31. McDermott D., Lebbé C., Hodi F.S., Maio M., Weber J.S., Wolchok J.D., Thompson J.A., Balch C.M. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat. Rev. 2014, 40:1056-1064.
32. Neyt K., Perros F., GeurtsvanKessel C.H., Hammad H., Lambrecht B.N. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012, 33:297-305.
33. Pace L., Tempez A., Arnold-Schrauf C., Lemaitre F., Bousso P., Fetler L., Sparwasser T., Amigorena S. Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory. Science 2012, 338:532-536.
34. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
35. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
36. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin. Med. Res. 2005, 3:221-228.
37. Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., Zhang W., Sougnez C., Cibulskis K., Sidney J., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124:453-462.
38. Rao S., Tortola L., Perlot T., Wirnsberger G., Novatchkova M., Nitsch R., Sykacek P., Frank L., Schramek D., Komnenovic V., et al. A dual role for autophagy in a murine model of lung cancer. Nat. Commun. 2014, 5:3056.
39. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., Garbe C., Gogas H., Schachter J., Linette G., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013, 31:616-622.
40. Robbins S.H., Tessmer M.S., Van Kaer L., Brossay L. Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur. J. Immunol. 2005, 35:757-765.
41. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
42. Sather B.D., Treuting P., Perdue N., Miazgowicz M., Fontenot J.D., Rudensky A.Y., Campbell D.J. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J. Exp. Med. 2007, 204:1335-1347.
43. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013, 1:32-42.
44. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
45. Snyder E.L., Watanabe H., Magendantz M., Hoersch S., Chen T.A., Wang D.G., Crowley D., Whittaker C.A., Meyerson M., Kimura S., Jacks T. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 2013, 50:185-199.
46. Suffia I., Reckling S.K., Salay G., Belkaid Y. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 2005, 174:5444-5455.
47. Teng M.W., Ngiow S.F., von Scheidt B., McLaughlin N., Sparwasser T., Smyth M.J. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010, 70:7800-7809.
48. Thornton E.E., Looney M.R., Bose O., Sen D., Sheppard D., Locksley R., Huang X., Krummel M.F. Spatiotemporally separated antigen uptake by alveolar dendritic cells and airway presentation to T cells in the lung. J. Exp. Med. 2012, 209:1183-1199.
49. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
50. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.